Exact Mass: 243.1219
Exact Mass Matches: 243.1219
Found 118 metabolites which its exact mass value is equals to given mass value 243.1219
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Agomelatine
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
Prolyl-Glutamine
Prolyl-Glutamine is a dipeptide composed of proline and glutamine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Glutaminylproline
Glutaminylproline is a dipeptide composed of glutamine and proline. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Prolyl-Gamma-glutamate
Prolyl-Gamma-glutamate is a dipeptide composed of proline and gamma-glutamate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
1-Azabicyclo[2.2.2]octan-3-one, 2-[(4-methoxyphenyl)methylene]-
2(1H)-quinolinone, 4-hydroxy-1-methyl-3-(3-methyl-2-butenyl)-
2,2,10-trimethyl-2,3,4,10-tetrahydro-5H-pyrano[2,3-b]quinolin-5-one
2-{[1-(2-Amino-acetyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid
Agomelatine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
Pro-GLN
A dipeptide formed from L-proline and L-glutamine residues.
(1-Furan-2-yl-but-3-enyl)-(4-methoxy-phenyl)-amine
4-(3-methylbutoxy)pyridine-2-carboximidamide,hydrochloride
1,2,3,5-Tetrahydro-spiro[4H-1-benzazepine-4,1-[2]cyclopentene]-3-carboxylic acid
1-(4-DIMETHYLAMINO-2-FLUORO-PHENYL)-3-(4-DIMETHYLIMMONIUM-2-FLUORO-CYCLOHEXA-2,5-DIEN-1-YLIDENE)-2-OXO-CYCLOBUTEN-4-OLATE
(3S,4R,5R,6S)-4-OXO-PENTANOICACID4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-P-TOLYLSULFAN
6-ETHYL-2-METHYLQUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER
4-OXO-PIPERIDINE-1-CARBOXYLIC ACID 2-TRIMETHYLSILANYL-ETHYL ESTER
1H-Indole,2-(1,1-dimethylethyl)-2,3-dihydro-5-(trifluoromethyl)-(9CI)
2,5,8-TRIMETHYLQUINOLINE-3-CARBOXYLIC ACID ETHYL ESTER
N-(1-(2-HYDROXY-NAPHTHALEN-1-YL)-PROPYL)-ACETAMIDE
6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-amine hydrochloride
N-METHYL-1-(1,3,5-TRIMETHYL-1H-PYRAZOL-4-YL)METHANAMINE
1-(2,5-Dimethoxy-4-i-propylthiophenyl)-2-aminopropane
1,3,5-Triazine-2,4-diamine, N-ethyl-N-(1-methylethyl)-6-(methylsulfinyl)-
(2E)-2-[(4-methoxyphenyl)methylidene]-1-azabicyclo[2.2.2]octan-3-one
(2S)-2-amino-5-oxo-5-[[(3S)-2-oxopiperidin-3-yl]amino]pentanoic acid
2-methyl-N-(2,4,6-trimethylphenyl)-3-furancarboxamide
(2S)-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]propanoic Acid
Ala-Gly-Pro
A tripeptide composed of L-alanine, glycine, and L-proline joined in sequence by peptide linkages.